Top-News

KAROLINSKA DEVELOP.AB News

Aktie
WKN:  A0M84G ISIN:  SE0002190926 US-Symbol:  KDEVF
0,1364 €
-0,0002 €
-0,15%
14.06.24 21:13:18
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-

KAROLINSKA DEVELOP.AB News

22.07.22 - GlobeNewswire
Karolinska Developments portfolio company Promimic and Danco Medical form a joint venture for the US-market
STOCKHOLM, SWEDEN, July 22 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic and the US-based company ...
04.07.22 - GlobeNewswire
Karolinska Development expands its portfolio following an investment in PharmNovo
STOCKHOLM, SWEDEN, July 4, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) has completed a previously announced investment in PharmNovo, thereby including ...
27.06.22 - GlobeNewswire
Karolinska Development’s portfolio company Svenska Vaccinfabriken presents scientific advancements at international conference
STOCKHOLM, Sweden, June 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Svenska Vaccinfabriken has presented ...
23.06.22 - GlobeNewswire
Karolinska Development’s portfolio company Promimic presents preclinical results showing decreased bacterial adhesion to implants
STOCKHOLM, Sweden, June 23, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Promimic today presented preclinical results ...
19.05.22 - GlobeNewswire
Karolinska Development's portfolio company Umecrine Cognition submits a Clinical Trial Application to initiate a phase 2 clinical trial with golexanolone
STOCKHOLM, SWEDEN – May 19, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has submitted a ...
17.05.22 - GlobeNewswire
Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals
STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the ...
02.05.22 - GlobeNewswire
Karolinska Development’s portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients
STOCKHOLM, Sweden, May 2, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen is preparing a Phase 2 clinical trial of ...
29.04.22 - GlobeNewswire
Karolinska Development’s portfolio company Promimic’s stock starts trading today
STOCKHOLM, Sweden, April 29 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Promimic’s stock starts trading today at Nasdaq ...
25.04.22 - GlobeNewswire
Karolinska Development’s portfolio company Promimic’s IPO offering fully subscribed
STOCKHOLM, Sweden, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic’s IPO offering was fully ...
25.04.22 - GlobeNewswire
Karolinska Development's portfolio company OssDsign completes patient enrolment to the TOP FUSION study
STOCKHOLM, SWEDEN, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has enrolled all patients in ...
04.04.22 - GlobeNewswire
Karolinska Development's portfolio company OssDsign enrolls the first patient to the multi-center registry PROPEL
STOCKHOLM, SWEDEN, April 4, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has enrolled the first patient ...
23.03.22 - GlobeNewswire
Karolinska Development's portfolio company OssDsign signs long-term contract with largest hospital network in France
STOCKHOLM, SWEDEN – March 23, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has signed a long-term ...
21.02.22 - GlobeNewswire
The rights issue is registered and the trading in Paid Subscription Shares ceases
Karolinska Development AB (publ) ("Karolinska Development" or the “Company") has completed a rights issue of shares that closed on February 2, 2022. The rights issue is now ...
03.02.22 - GlobeNewswire
Karolinska Development's portfolio company AnaCardio raises SEK 33 million to progress clinical development of a novel therapy for heart failure
STOCKHOLM, SWEDEN February 3, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed a ...
11.01.22 - GlobeNewswire
Karolinska Development's portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms
STOCKHOLM, SWEDEN – 11 January 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented ...
11.01.22 - GlobeNewswire
Karolinska Development's portfolio company Svenska Vaccinfabriken appoints Richard Bethell as new CEO
STOCKHOLM, SWEDEN 11 January 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Svenska Vaccinfabriken has ...
13.12.21 - GlobeNewswire
Organon’s acquisition of Karolinska Development's portfolio company Forendo Pharma has been successfully completed
STOCKHOLM SWEDEN – December 13, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the previously announced transaction, in which the ...
01.12.21 - GlobeNewswire
Karolinska Development’s portfolio company Modus Therapeutics initiates Phase 1b trial of its drug candidate sevuparin
STOCKHOLM SWEDEN – December 1, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics has dosed ...
09.11.21 - GlobeNewswire
Karolinska Development’s portfolio company receives approval to initiate a clinical Phase 1b trial with sevuparin in the Netherlands
STOCKHOLM, SWEDEN – November 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Modus Therapeutics has received ...
03.11.21 - GlobeNewswire
Karolinska Development’s portfolio company Umecrine Cognition presents new data supporting the development of golexanolone as a treatment of primary biliary cholangitis
STOCKHOLM, SWEDEN – November 3, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Umecrine Cognition will present ...

Newssuche

Videos

newspaper
13.06.24 -3,86%
Technical Trading: Zukauf-​Chance bei Top-Trade, wenn
Sugar No.11 Long Typ: Turbo Open End WKN: VV50DP Hebel: 5 Laufzeit: OpenEnd Einstieg: prozyklisch ... Mehr »